Who should be considered for islet transplantation alone? N Othonos, P Choudhary Current diabetes reports 17, 1-7, 2017 | 19 | 2017 |
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial N Othonos, R Pofi, A Arvaniti, S White, I Bonaventura, N Nikolaou, ... Nature Communications 14 (1), 1025, 2023 | 12 | 2023 |
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents JM Hazlehurst, TR Lim, C Charlton, JJ Miller, LL Gathercole, T Cornfield, ... Metabolism open 14, 100177, 2022 | 9 | 2022 |
Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids N Othonos, T Marjot, C Woods, JM Hazlehurst, N Nikolaou, R Pofi, ... The Journal of Clinical Endocrinology & Metabolism 105 (9), e3316-e3328, 2020 | 9 | 2020 |
Glucocorticoid metabolism and activation N Othonos, J Tomlinson Academic Press, 2019 | 4 | 2019 |
11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: a randomized, double-blind, placebo … N Othonos, R Pofi, A Arvaniti, A Whittaker, P Stewart, R Coleman, ... Endocrine Abstracts 70, 2020 | 1 | 2020 |
The outcome of dapagliflozin use in a reallife clinical setting in multi-district general hospitals RB Kannan, N Othonos, G Dimitriadis, T Barber, N Murthy, J Young, ... DIABETIC MEDICINE 32, 173-173, 2015 | 1 | 2015 |
11 [beta]-hydroxysteroid dehydrogenase type 1 inhibition unmasks multiple pathways that may mitigate the adverse effects of prescribed prednisolone R Pofi, S Coll, N Othonos, H Miller, T Potter, J Escott, A Whittaker, ... Endocrine Abstracts 99, 2024 | | 2024 |
Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition C Gómez, Z Alimajstorovic, N Othonos, DV Winter, S White, GG Lavery, ... British Journal of Pharmacology 181 (5), 698-711, 2024 | | 2024 |
Identification of a human blood biomarker of pharmacological 11β-hydroxysteroid dehydrogenase 1 inhibition CG Castella, Z Alimajstorovic, N Othonos, D Winter, S White, G Lavery, ... Authorea Preprints, 2023 | | 2023 |
The impact of pre-receptor metabolism on the adverse effects of exogenous glucocorticoids N Othonos University of Leeds, 2020 | | 2020 |
Co-administration of 5 [alpha]-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids T Marjot, N Othonos, C Woods, J Hazlehurst, A Moolla, L Hodson, ... Endocrine Abstracts 50, 2017 | | 2017 |
The adverse effects of prescribed glucocorticoids are worsened by co-administration of 5 [alpha]-reductase inhibitors T Marjot, N Othonos, C Woods, J Hazlehurst, A Moola, L Hodson, ... Endocrine Abstracts 49, 2017 | | 2017 |
Continuous intra-peritoneal insulin infusion: an alternative option for insulin administration N Othonos, S Khorsandi, A Pernet, G Gallen, P Srinivasan, P Choudhary DIABETIC MEDICINE 34, 16-16, 2017 | | 2017 |
Clinical care and other categories posters N Othonos, S Khorsandi, A Pernet, G Gallen, P Srinivasan, P Choudhary, ... | | 2017 |
A comparative study of women with gestational diabetes vs a high risk group without gestational diabetes and their antenatal and neonatal outcomes N Othonos, G Dimitriadis, C Sherry, R Rao, W Goodwin, S Eastman, ... DIABETIC MEDICINE 32, 177-177, 2015 | | 2015 |
Diabetes: the forgotten complication of parathyroidectomy N Othonos, V Patel, R Nair, S Ayre, P Saravanan Endocrine Abstracts 34, 2014 | | 2014 |
Type 1 diabetes+ metabolic syndrome: need for a different management paradigm? N Othonos, V Patel, P Saravanan DIABETIC MEDICINE 31, 181-181, 2014 | | 2014 |
Audit of the management of diabetic ketoacidosis in a large teaching hospital, before adoption of national guidelines K Seejore, MH Bholah, SE Jones, S Drake, N Othonos, A Abbas DIABETIC MEDICINE 30, 81-82, 2013 | | 2013 |
Suboptimal control on metformin and sulfonylurea: what next? N Othonos, A Abbas Prescriber 24 (3), 15-20, 2013 | | 2013 |